Affinity Biopharmaceutical Co., Ltd., Shanghai, China.

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Zai Lab will highlight potential of ZL-1310 as a promising ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company’s ...

The emergence of antibody–drug conjugates (ADCs) shows promise for treating a variety of tumours by using target-specific monoclonal antibodies to deliver cytotoxic substances directly to cancer cells ...

National Cancer Institute, National Institutes Of Health (NIH), Bethesda, MD.

Gansu Provincial Key Laboratory of Environmental Oncology, Department of Tumor Center, Lanzhou University Second Hospital, Second Clinical Medical School, Lanzhou University, Lanzhou 730000, China ...